Background:L-arginine (L-arg) participates in numerous biological functions including urea and nitric oxide synthesis. Sources of L-arg include dietary proteins and endogenous synthesis by argininosuccinate synthetase and argininosuccinate lyase. L-arg is converted to urea by arginase I in the liver and arginase II in the kidney. Normally, the liver fully consumes L-arg for urea generation and does not contribute to its circulating pool. Instead, much of the circulating L-arg is produced by the kidney. If true, plasma L-arg should be severely reduced in chronic renal failure (CRF); however, plasma L-arg is frequently unchanged in CRF. We hypothesized that preservation of plasma L-arg in CRF may be, partly, due to downregulation/inhibition of arginase. Methods: Argininosuccinate synthetase, arginase I and II protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5/6 nephrectomy or sham operation. In addition, arginase activity was measured in the presence of different urea concentrations to simulate azotemia in vitro. Results: Arginases I and II protein abundance as well as arginase activity in the liver, measured in the physiological buffer, were similar among the CRF and control groups. However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of arginase activity by urea in the tissue lysates. CRF had no significant effect on argininosuccinate synthetase abundance in the kidney, liver, spleen or intestine. Conclusions: Although CRF does not change the abundance or intrinsic properties of arginase, the inherent rise in urea concentration inhibits its enzymatic activity. The latter, in turn, attenuates L-arg catabolism and urea production and, thereby, mitigates the fall in plasma L-arg.

1.
Brosnan ME, Brosnan JT: Renal arginine metabolism. J Nutr 2004;134:2791S–2795S.
2.
Morel F, Hus-Citharel A, Levillain O: Biochemical heterogeneity of arginine metabolism along kidney proximal tubules. Kidney Int 1996;49:1608–1610.
3.
Featherston WR, Rogers QR, Freedland RA: Relative importance of kidney and liver synthesis of arginine by the rat. Am J Physiol 1973;224:127–129.
4.
Felig P, Wahren J: Amino acid metabolism in exercising man. J Clin Invest 1971;50:2703–2714.
5.
Levillain O, Hus-Citharel A, Morel F, Bankir L: Localization of arginine synthesis in mouse and rabbit nephron: localization and functional significance. Am J Physiol 1993;264:F1038–F1045.
6.
Hurwitz R, Kretchmer N: Development of arginine synthesizing enzymes in mouse intestine. Am J Physiol 1986;251:G103–G110.
7.
Windmueller HG, Spaeth AE: Source and fate of circulating citrulline. Am J Physiol 1981;241:E473–E480.
8.
Zamora SA, Amin HG, McMillan DD, Kubes P, Fick GH, Butzner JD, Parson HG, Scot RB: Plasma L-arginine concentrations in premature infants with necrotizing enterocolitis. J Pediatr 1997;131:226–232.
9.
Husson A, Brasse-Lagnel C, Fairand A, Renouf A, Lavoinne A: Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem 2003;270:1887–1899.
10.
Reyes AA, Karl IE, Klahr S: Role of arginine in health and in renal disease. Am J Physiol 1994;267:F331–346.
11.
White MF, Christensen HN: Cationic amino acid transport into cultured animal cells. II. Transport system barely perceptible in ordinary hepatocytes, but active in hepatoma cell lines. J Biol Chem 1982;258:8028–8038.
12.
Ash DE: Structure and function of arginases. J Nutr 2004;134:2760S–2764S.
13.
Kuhlmann MK, Kopple JD: Amino acid metabolism in the kidney. Semin Nephrol 1990;10:445–457.
14.
Jungers P, Chauveau I, Ceballos J, Bardet P, Parvy T, Hannendouche P: Plasma free amino acid alterations from early to end-stage chronic renal failure. J Nephrol 1994;7:48–54.
15.
Tizianello A, De Ferrari G, Garibotto G, Gurrei G, Robaudo C, Acquarone N, Ghiggeri GM: Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980;65:1162–1173.
16.
Baylis C: Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2006;2:209–220.
17.
Bouby N, Hassler C, Parvy P, Bankir L: Renal synthesis of arginine in chronic renal failure: in vivo and in vitro studies in rats with 5/6 nephrectomy. Kidney Int 1993;44:676–683.
18.
Natesan S, Reddy SR: Compensatory changes in enzymes of arginine metabolism during renal hypertrophy in mice. Comp Biochem Physiol B Biochem Mol Biol2001;130:585–595.
19.
Davis T, Karl IE, Tegtmeyer E, Osborne D, Klahr S, Harter HR: Muscle protein turnover: effects of exercise training and renal insufficiency. Am J Physiol 1998;248:E337–E345.
20.
Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ: Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol 1998;274:F642–F649.
21.
Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal Biochem 1976;72:248–254.
22.
Ochoa JB, Bernard A, Mistry S, Morris S, Figert P, Maley M, Tsuei B, Boulanger B, Kearney P: Trauma increases extra-hepatic arginase activity. Surgery 2000;127:419–426.
23.
Kornarska L, Tomaszewski L: A simple quantitative micromethod or arginase assay in blood spots dried on filter paper. Clin Chim Acta 1986;154:7–17.
24.
Reyes A, Purkerson M, Karl I, Klahr S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 1992;20:168–176.
25.
Vaziri ND, Oveisi F, Ding Y: Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 1998;53:1748–1754.
26.
Ceballos I, Chauveau P, Guerin V, Bardet J, Parvy P, Kamoun P, Jungers P: Early alterations of plasma amino acids in chronic renal failure. Clin Chim Acta 1990;188:101–108.
27.
Kihlberg R, Sterner G, Wennberg A, Denneberg T: Plasma amino acid level in uremic rats given high and low diets or intravenous infusions of amino acid solutions. J Nutr 1982;112:2058–2070.
28.
Fukuda S, Kopple J: Uptake and release of amino acids by the kidney of dogs made chronically uremic with uranyl nitrate. Miner Electrolyte Metab 1980;3:248–260.
29.
Boorsook H, Dubnoff JW: The conversion of citrillune to arginine in kidney. J Biol Chem 1941;140:717–738.
30.
Dhanakoti SN, Brosnan JT, Brosnan ME, Herzberg GE: Net renal arginine flux in rats is not affected by dietary arginine or protein dietary intake. J Nutr 1992;122:1127–1164.
31.
Marks DB, Marks AD, Smith C: Basic Medical Biochemistry. Baltimore, Williams & Wilkins, 1996, pp 99–128.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.